Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Snapshot

Set Alert for Market Snapshot

IBD Market Snapshot: Payers May Shift Preferred Products To Accommodate New Drugs

Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.

Gastrointestinal Market Access

IBD Market Snapshot: New Medicines Try To Address Patient, Physician Demands

Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.

Clinical Trials Market Intelligence

IBD Market Snapshot: Changes Ahead, But Current Biologics Are Formidable Competitors

The ulcerative colitis and Crohn’s disease landscapes may shift soon but new drugs will compete with entrenched blockbusters, including Humira, Stelara and Entyvio, with biosimilars on the way.

Launches Market Intelligence

MS Market Snapshot: New Options Confront Commercial Reality Of A Crowded Space

The multiple sclerosis drug market is more competitive than ever, though new options work through existing mechanisms of action. Unmet need remains despite numerous drugs, and competition clustered in the same classes creates pressure.

Immune Disorders Market Intelligence

SMA Market Snapshot: Future Spinraza Patent Loss Makes Room For Promising Myostatin Inhibitors

While spinal muscular atrophy therapies Evrysdi and Zolgensma have gained ground at the expense of pioneer Spinraza, emerging myostatin inhibitors promise a complementary mechanism that could enhance functional outcomes.

Market Snapshot Neurology

Hereditary Angioedema Market Snapshot: Room For Pills And Injections As Prophylaxis Makes Gains

While many HAE patients converted from injectable prophylaxis to BioCryst’s oral Orladeyo last year, physicians said a promising injectable candidate from Ionis could benefit from varied patient preference.

Market Snapshot Rare Diseases

New Products Shake Up Overlooked Bipolar Disorder Market

The highly genericized bipolar disorder market is set for change as both new long-acting injectable formulations of older products and novel therapies reach the market, while firms like NRx and BioXcel target major unmet needs in a disease that needs more R&D.

Market Snapshot Research & Development

A Deep Dive Into The Game-Changing Drugs For Skin Diseases

Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.

Approvals Dermatology

Pneumococcal Vaccines Market Snapshot: Pfizer And Merck Face Off

Pfizer's Prevnar 20 and Merck's Vaxneuvance are launching simultaneously and are expected to help drive vaccines growth for both big pharmas.

Launches Vaccines

Wet AMD Market Snapshot: A High-Growth Market Poised For Change

Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.

Ophthalmic Market Snapshot

UC Market Gets Increasingly Crowded – But High Unmet Need Remains

Market Snapshot: The ulcerative colitis market looks set to experience strong pricing pressure over the next three to five years, with leading players losing exclusivity for their drugs and a flood of novel entrants set to hit the market.

Launches Approvals

The Extraordinary But Uncertain Growth Of The COVID-19 Market

The value of the COVID-19 market reached more than $8bn in the first quarter, fuelled by mRNA-based vaccines, but the future growth of the sector depends on the rather unpredictable course of the pandemic, and the response of healthcare providers and countries.

Coronavirus COVID-19 Market Snapshot
See All
UsernamePublicRestriction

Register